Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Calliditas Therapeutics AB (publ)
  6. News
  7. Summary
    CALTX   SE0010441584

CALLIDITAS THERAPEUTICS AB (PUBL)

(CALTX)
  Report
Delayed Nasdaq Stockholm  -  11:29:56 2023-02-03 am EST
97.10 SEK   -0.82%
02/02Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy
AQ
02/02Calliditas Therapeutics AB Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA Nephropathy
CI
01/31Calliditas Therapeutics : Press Release dated January 31, 2023 - Form 6-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

European ADRs Move Higher in Friday Trading

10/21/2022 | 11:19am EST


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ACHILLES CORPORATION -0.08% 1244 Delayed Quote.0.16%
ACHILLES THERAPEUTICS PLC -0.83% 1.2 Delayed Quote.33.33%
ADAPTIMMUNE THERAPEUTICS PLC -4.05% 1.66 Delayed Quote.18.49%
ARCELORMITTAL 0.53% 28.61 Real-time Quote.16.42%
BICYCLE THERAPEUTICS PLC -3.55% 27.44 Delayed Quote.-7.30%
BIONTECH SE -1.62% 142.06 Delayed Quote.-5.43%
CALLIDITAS THERAPEUTICS AB (PUBL) -0.82% 97.1 Delayed Quote.5.03%
CELLECTIS S.A. -20.67% 2.38 Real-time Quote.19.78%
ENDAVA PLC -0.94% 93.12 Delayed Quote.21.73%
INTERCONTINENTAL HOTELS GROUP PLC 0.10% 5784 Delayed Quote.21.92%
MORPHOSYS AG -1.68% 19 Delayed Quote.43.83%
MYNARIC AG 3.82% 16.3 Delayed Quote.0.62%
ORCHARD THERAPEUTICS PLC 1.53% 0.5774 Delayed Quote.53.29%
RIO TINTO PLC 1.06% 6128 Delayed Quote.5.69%
SILENCE THERAPEUTICS PLC 30.00% 3.25 Delayed Quote.0.00%
SPARK NETWORKS SE 5.61% 1.13 Delayed Quote.73.85%
WISEKEY INTERNATIONAL HOLDING AG -0.90% 0.2205 Delayed Quote.31.88%
All news about CALLIDITAS THERAPEUTICS AB (PUBL)
02/02Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in Ig..
AQ
02/02Calliditas Therapeutics AB Receives Conditional Marketing Authorization from UK MHRA fo..
CI
01/31Calliditas Therapeutics : Press Release dated January 31, 2023 - Form 6-K
PU
01/31Number of shares and votes in Calliditas Therapeutics
AQ
2022Calliditas Therapeutics Says China's Center for Drug Evaluation Recommends Kidney Disea..
MT
2022Calliditas Therapeutics JV's Primary IgA Nephropathy Drug Gets Priority Review Recommen..
MT
2022China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA ..
AQ
2022Calliditas Therapeutics Announces China CDE/NMPA Recommends Priority Review for Nefecon..
CI
2022Number of shares and votes in Calliditas Therapeutics
AQ
2022Calliditas Therapeutics Chief Executive Buys 50,000 Shares in Warrant Program
MT
More news
Analyst Recommendations on CALLIDITAS THERAPEUTICS AB (PUBL)
More recommendations
Financials
Sales 2022 634 M 60,3 M 60,3 M
Net income 2022 -469 M -44,7 M -44,7 M
Net cash 2022 148 M 14,1 M 14,1 M
P/E ratio 2022 -12,3x
Yield 2022 -
Capitalization 5 785 M 551 M 551 M
EV / Sales 2022 8,89x
EV / Sales 2023 2,35x
Nbr of Employees 98
Free-Float 86,1%
Chart CALLIDITAS THERAPEUTICS AB (PUBL)
Duration : Period :
Calliditas Therapeutics AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CALLIDITAS THERAPEUTICS AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 97,10 SEK
Average target price 246,80 SEK
Spread / Average Target 154%
EPS Revisions
Managers and Directors
Renée Julie Elisabet Aguiar-Lucander Chief Executive Officer
Fredrik Johansson Chief Financial Officer
Elmar J. Schnee Chairman
Patrik Sobocki Chairman
Johan Erik Häggblad Chief Scientific Officer